Analyst Price Targets — BCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:16 am | — | RBC Capital | $14.00 | $10.17 | TheFly | BioCryst price target raised to $14 from $13 at RBC Capital |
| June 30, 2026 11:33 am | — | Cantor Fitzgerald | $29.00 | $9.55 | TheFly | BioCryst price target raised to $29 from $27 at Cantor Fitzgerald |
| June 30, 2026 8:42 am | Maury Raycroft | Jefferies | $17.00 | $9.55 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies |
| November 5, 2025 10:41 am | Jonathan Wolleben | JMP Securities | $25.00 | $6.97 | TheFly | BioCryst price target lowered to $25 from $27 at Citizens JMP |
| November 4, 2025 10:07 am | — | Barclays | $9.00 | $6.86 | TheFly | BioCryst price target lowered to $9 from $11 at Barclays |
| October 14, 2025 7:51 pm | — | RBC Capital | $15.00 | $6.42 | TheFly | BioCryst weakness presents 'compelling' buying opportunity, says RBC |
| October 14, 2025 7:21 pm | Maury Raycroft | Jefferies | $15.00 | $6.42 | TheFly | BioCryst price target raised to $15 from $14 at Jefferies |
| October 1, 2025 12:36 pm | — | Evercore ISI | $8.00 | $7.24 | TheFly | BioCryst downgraded to In Line from Outperform at Evercore ISI |
| August 6, 2024 5:31 am | Gena Wang | Barclays | $7.00 | $7.51 | TheFly | BioCryst price target raised to $7 from $6 at Barclays |
| August 5, 2024 4:01 pm | Maury Raycroft | Jefferies | $11.00 | $7.51 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies |
Latest News for BCRX
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient…
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as…
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.